AAP
TVTX icon

Arax Advisory Partners’s Travere Therapeutics TVTX Stock Holding History

Arax Advisory Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.2K Buy
743
+638
+608% +$19.1K ﹤0.01% 1881
2025
Q4 		$4.01K Sell
105
-1,448
-93% -$47.1K ﹤0.01% 2968
2025
Q3 		$37.1K Buy
+1,553
New +$29.2K ﹤0.01% 1983
2025
Q2 		– Sell
-1,046
Closed -$18.7K – 3192
2025
Q1 		$18.7K Buy
1,046
+949
+978% +$19.3K ﹤0.01% 1326
2024
Q4 		$1.69K Hold
97
– – ﹤0.01% 2047
2024
Q3 		$1.36K Hold
97
– – ﹤0.01% 2167
2024
Q2 		$798 Buy
+97
New +$653 ﹤0.01% 2238

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arax Advisory Partners's TVTX Position: Q1 2026 in Review

Arax Advisory Partners increased its Travere Therapeutics (TVTX) stake by 608% in Q1 2026, buying an estimated $19.1K and bringing the position to 743 shares worth $31.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1881.

Arax Advisory Partners first reported a position in TVTX in Q2 2024 and has held it in 7 quarters since. The position peaked at $37.1K in Q3 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Arax Advisory Partners held 743 shares of Travere Therapeutics worth $31.2K as of Q1 2026.
  • Arax Advisory Partners bought 638 Travere Therapeutics shares in Q1 2026, an estimated $19.1K.
  • Travere Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #1881 holding.
  • Arax Advisory Partners first reported a position in Travere Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Arax Advisory Partners's Travere Therapeutics position peaked at $37.1K in Q3 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.